These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 4911257)

  • 1. Oral L-dopa treatment of parkinsonism.
    Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
    Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
    [No Abstract]   [Full Text] [Related]  

  • 2. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinsonism and DOPA.
    Cotzias GC; Papavasiliou PS; Gellene R; Aronson RB
    Trans Assoc Am Physicians; 1968; 81():171-83. PubMed ID: 4889342
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines].
    Uono M; Tanabe H; Yano Y; Nakao K
    No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082
    [No Abstract]   [Full Text] [Related]  

  • 5. L-Dopa treatment in Parkinson's Disease.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1970; 4(6):348-69. PubMed ID: 4932969
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the metabolism and excretion of L-3,4-dihydroxyphenylalanine (L-DOPA) in human beings by gas chromatography.
    Imai K; Sugiura M; Kubo H; Tamura Z; Oya K
    Chem Pharm Bull (Tokyo); 1972 Apr; 20(4):759-64. PubMed ID: 5045616
    [No Abstract]   [Full Text] [Related]  

  • 7. Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa.
    Bertler A; Jeppsson PG; Nordgren L; Rosengren E
    Acta Neurol Scand; 1971; 47(4):393-402. PubMed ID: 4941731
    [No Abstract]   [Full Text] [Related]  

  • 8. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 9. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
    Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA
    N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085
    [No Abstract]   [Full Text] [Related]  

  • 10. Biochemical investigations in patients with Parkinson's disease treated with L-dopa.
    Jequier E; Dufresne JJ
    Neurology; 1972 Jan; 22(1):15-21. PubMed ID: 5061836
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined L-dopa and amantadine in Parkinsonism.
    Pollock M; Jorgensen PB
    Aust N Z J Med; 1972 Aug; 2(3):252-5. PubMed ID: 4564049
    [No Abstract]   [Full Text] [Related]  

  • 12. Pyridoxine, DOPA, and Parkinsonism.
    Yahr MD; Duvoisin RC; Côté L; Cohen G
    Adv Biochem Psychopharmacol; 1972; 4():185-94. PubMed ID: 4555927
    [No Abstract]   [Full Text] [Related]  

  • 13. Metabolism and clinical assessment of L-dopa in parkinsonism.
    Ericsson AD; McCann D; Sharpless N; Reveno W
    Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Parkinson's disease with amantadine and L-Dopa.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa: alterations in behavior.
    Goodwin FK; Murphy DL; Brodie HK; Bunney WE
    Clin Pharmacol Ther; 1971; 12(2):383-96. PubMed ID: 4930867
    [No Abstract]   [Full Text] [Related]  

  • 16. L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism.
    Weiner W; Harrison W; Klawans H
    Life Sci; 1969 Sep; 8(17):971-6. PubMed ID: 5808572
    [No Abstract]   [Full Text] [Related]  

  • 17. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined treatment of parkinsonism with L-dopa and amantadine.
    Godwin-Austen RB; Frears CC; Bergmann S; Parkes JD; Knill-Jones RP
    Lancet; 1970 Aug; 2(7669):383-5. PubMed ID: 4194690
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of L-dopa in Parkinson's disease.
    Godwin-Austen RB; Tomlinson EB; Frears CC; Kok HW
    Lancet; 1969 Jul; 2(7613):165-8. PubMed ID: 4183130
    [No Abstract]   [Full Text] [Related]  

  • 20. The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.
    Curzon G; Godwin-Austen RB; Tomlinson EB; Kantamaneni BD
    J Neurol Neurosurg Psychiatry; 1970 Feb; 33(1):1-6. PubMed ID: 5418176
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.